- Home
- EVAX
EVAX
Evaxion Biotech
as 09-12-2025 4:00pm EST
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
| Founded: | 2008 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 17.8M | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 88.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.20 - $17.20 | Next Earning Date: | 10-30-2025 |
| Revenue: | $3,176,000 | Revenue Growth: | 1042.45% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Evaxion Biotech News
EVAX Breaking Stock News: Dive into EVAX Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
MT Newswires
8 days ago
European Equities Traded in the US as ADRs Are Little Changed in Friday Trading
MT Newswires
9 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
GlobeNewswire
3 months ago
Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus
Zacks Small Cap Research
3 months ago
EVAX AI Technology Produces New Vaccine Candidate
MT Newswires
3 months ago
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
MT Newswires
3 months ago
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
GlobeNewswire
3 months ago
Evaxion receives grant funding to design new polio vaccine
Compare EVAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EVAX Evaxion Biotech - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.